Comparative Shotgun Proteomics Reveals the Characteristic Protein Signature of Osteosarcoma Subtypes
Authors:
- Maram AlaaMAMaram Alaa
- Nouran Al-ShehabyNANouran Al-Shehaby
- Ali Mostafa AnwarAAAli Mostafa Anwar
- Nesma FaridNFNesma Farid
- Mustafa Shaban ShawkyMSMustafa Shaban Shawky
- Manal ZamzamMZManal Zamzam
- Iman ZakyIZIman Zaky
- Ahmed ElghounimyAEAhmed Elghounimy
- Shahenda El-NaggarShahenda El-Naggar
- Sameh MagdeldinSMSameh Magdeldin
Open Access
Abstract
Osteosarcoma is a primary malignant bone tumor affecting adolescents and young adults. This study aimed to identify proteomic signatures that distinguish between different osteosarcoma subtypes, providing insights into their molecular heterogeneity and potential implications for personalized treatment approaches. Using advanced proteomic techniques, we analyzed FFPE tumor samples from a cohort of pediatric osteosarcoma patients representing four various subtypes. Differential expression analysis revealed a significant proteomic signature that discriminated between these subtypes, highlighting distinct molecular profiles associated with different tumor characteristics. In contrast, clinical determinants did not correlate with the proteome signature of pediatric osteosarcoma. The identified proteomics signature encompassed a diverse array of proteins involved in focal adhesion, ECM-receptor interaction, PI3K-Akt signaling pathways, and proteoglycans in cancer, among the top enriched pathways. These findings underscore the importance of considering the molecular heterogeneity of osteosarcoma during diagnosis or even when developing personalized treatment strategies. By identifying subtype-specific proteomics signatures, clinicians may be able to tailor therapy regimens to individual patients, optimizing treatment efficacy and minimizing adverse effects.Keywords
Funding Information
- Egypt Cancer Network, USA (ECN)
- Children’s Cancer Hospital, Egypt 57357
This publication has 54 references indexed in Scilit:
- Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factorsIndian Journal of Orthopaedics, 2014
- Proteomics of osteosarcomaExpert Review of Proteomics, 2014
- Telangiectatic OsteosarcomaArchives of Pathology & Laboratory Medicine, 2012
- Lumican regulates osteosarcoma cell adhesion by modulating TGFβ2 activityThe International Journal of Biochemistry & Cell Biology, 2011
- The Epidemiology of Osteosarcoma2009
- Formation and function of Weibel-Palade bodiesJournal of Cell Science, 2008
- Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cellsThe FEBS Journal, 2007
- Probabilistic Quotient Normalization as Robust Method to Account for Dilution of Complex Biological Mixtures. Application in 1H NMR MetabonomicsAnalytical Chemistry, 2006
- Anomalous Cadherin Expression in OsteosarcomaThe American Journal of Pathology, 1999
- Biglycan Gene Promoter Activity in Osteosarcoma Cells Is Regulated by Cyclic AMPBiochemical and Biophysical Research Communications, 1997